CliffBio
small molecule

INVIRASE

SAQUINAVIR MESYLATE

Loss of exclusivity—loss of exclusivity
CompanyHOFFMANN LA ROCHE INC

Drug detail

Brand nameINVIRASE
Active ingredientSAQUINAVIR MESYLATE
StrengthEQ 200MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1995
Marketing statusDISCN

More from HOFFMANN LA ROCHE INC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

INVIRASE patent cliff — loss of exclusivity — | CliffBio